Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $31.86 Consensus Target Price from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Buy" by the nine research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $31.86.

A number of research analysts have weighed in on the company. Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday, May 23rd. HC Wainwright cut their price objective on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a report on Friday, May 16th. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Finally, Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective for the company in a report on Friday, May 23rd.

Bicara Therapeutics Stock Up 8.0%

BCAX stock traded up $0.86 during mid-day trading on Monday, reaching $11.65. 563,779 shares of the company traded hands, compared to its average volume of 592,148. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09. The company has a fifty day moving average price of $10.85 and a 200-day moving average price of $12.34.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). On average, equities analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Red Tree Management LLC bought a new stake in Bicara Therapeutics in the 4th quarter worth approximately $55,230,000. Vestal Point Capital LP lifted its position in Bicara Therapeutics by 290.0% in the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock worth $36,080,000 after buying an additional 2,058,975 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after buying an additional 1,375,265 shares during the last quarter. Braidwell LP lifted its position in Bicara Therapeutics by 8.1% in the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company's stock worth $28,181,000 after buying an additional 162,144 shares during the last quarter. Finally, Deep Track Capital LP lifted its position in Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock worth $34,840,000 after buying an additional 1,203,148 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.